Skip to main content

Study Finds No Benefit from Fish Oil Pills......


Study Finds No Benefit from Fish Oil Pills 




Fish oil pills don't reduce the risk of heart attack and stroke in people at high risk of heart disease, a new study suggests. Earlier studies concluded that eating fatty fish, such as salmon and tuna, could lower risk in people with heart failure or a previous heart attack. The new study focused on about 12,500 people who never had a heart attack or stroke. But they had high blood pressure, a family history of heart disease or several other factors that increased their risk. They already were taking medicines to address those risks. People were randomly divided into 2 groups. One group took a daily capsule containing omega-3 fatty acids found in fish. The other group took placebo pills that contained olive oil. In the next 5 years, about 12% of each group died or spent time in a hospital because of a heart attack, stroke or other heart-related problem. People who got the real fish oil did not have better results. The New England Journal of Medicine published the study. The Associated Press wrote about it May 9.
By Howard LeWine, M.D.

Popular posts from this blog

You Will Never Thought That Knowing What Is Health Insurance Could Be So Beneficial!

some useful vegetable for Breast Cancer prevention

Broccoli C auliflower Brussel Sprouts Spinach Coliards Tomatoes Kale Cabbage Carrots Have more sex.....Prevention Cancer  

FDA Panel Votes to Approve 'Female Viagra' With Conditions After Third Hearing

   By GILLIAN MOHNEY and LANA ZAK via Good Morning America An expert panel for the U.S. Food and Drug Administration voted today to approve a drug that has been dubbed the "female Viagra" after two previous attempts failed to gain approval. The FDA is set to make a final decision in August, and while the agency generally follows to the panelists' vote, it is not bound to adhere to it. Medical experts from the FDA examined the evidence on the effectiveness of the drug flibanserin, designed to help per-menopausal women with Hypo active Sexual Desire Disorder (HSDD). This is the third time the drug has been presented to the FDA, after previous attempts to get the drug approved failed in part due to the agency having concerns about whether its benefits outweighed the risks. A mother and her daughter were among those to offer emotional testimony to the FDA panel today. The mother, Barbara, talked about how her relationships with her husband and family became st